Osimertinib versus afatinib in patients with T790M-positive, non-small-cell lung cancer and multiple central nervous system metastases after failure of initial EGFR-TKI treatment

Table 1 Baseline characteristics

Variable	OSI (n = 60)	AFA (n = 64)	p value
Age (years)	64.24 ± 12.33	64.13 ± 13.72	0.72^a
Sex (male/female), No.%	25/35	28/36	0.82^b
BMI (kg/m²)	23.74 ± 2.31	24.15 ± 2.46	0.26^a
Smoking status, No.%			0.81^c
Never a smoker	11	13
Former smokers	32	30
Current smokers	17	21
Time from diagnosis of NSCLC (months), No.%			0.78^c
< 6	15	17
6–12	35	33
> 12	10	14
Largest size of brain metastasis, No.%			0.31^c
≤ 10 mm	22	18
> 10 mm	38	46
Number of brain metastases, No.%			0.47^c
≤ 3	32	30
> 3	28	34
Previous EGFR-TKI therapy, No.%			0.41^c
Erlotinib	23	20
Gefitinib	16	18
Afatinib	21	26
Type of EGFR mutation, No.%			0.91^c
T790M and Exon 19 deletion	35	38
T790M and Exon 21 L858R	25	26
Distant metastasis except for CNS, No.%			0.54^c
Gastrointestinal	22	18
Pancreas	11	14
Liver	12	16
Pancreas	12	14
Other	3	2
ECOG performance status, No.%			0.97^c
0	9	12
1	27	25
2	24	27

OSI osimertinib, AFA afatinib, BMI body mass index, NSCLC non-small-cell lung cancer, EGFR-TKI epidermal growth factor receptor-tyrosine kinase inhibitor, CNS central nervous system, ECOG Eastern Cooperative Oncology Group
^aAnalysed using independent-samples t-test
^bAnalysed using Chi-squared test
^cAnalysed using the Mann–Whitney test

ISSN: 1471-2466